Clinical Trial Update: Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating azacitidine plus the CAOLD regimen in relapsed or refractory Peripheral T-cell lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Navy General Hospital, Beijing | Conditions: Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas | Phase 1, Phase 2 | Status: RECRUITING